Evidence map›Paper›PMID 38701161›Full record

ArticleJournal of Parkinson's disease2024

Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol.

Marie-Louise Zeissler, Nikul Bakshi, Michèle Bartlett, Amit Batla, David Byrom, Rebecca Chapman, Sally Collins, Elaine Cowd, Eric Deeson, Romy Ellis-Doyle and 22 more

Abstract read
In one paragraph

Article in Journal of Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Marie-Louise ZeisslerUniversity of Plymouth, Plymouth, UK.
Nikul BakshiParkinson's UK, London, UK.
Michèle BartlettExpert Through Experience, UK.
Amit BatlaUniversity College London, London, UK.
David ByromExpert Through Experience, UK.
Rebecca ChapmanUniversity of Plymouth, Plymouth, UK.
Sally CollinsUniversity of Plymouth, Plymouth, UK.
Elaine CowdExpert Through Experience, UK.
Eric DeesonExpert Through Experience, UK.
Romy Ellis-DoyleUniversity College London, London, UK.
Jodie ForbesExpert Through Experience, UK.
Cristina Gonzalez-RoblesUniversity College London, London, UK.
Anna JewellExpert Through Experience, UK.
Emma L LaneCardiff University, Cardiff, UK.
Nancy R LaPelleWestborough, MA, USA.
Keith MartinExpert Through Experience, UK.
Helen MatthewsCure Parkinson's, London, UK.
Laurel MillerExpert Through Experience, UK.
Georgia MillsUniversity College London, London, UK.
Antony MorganExpert Through Experience, UK.
Miriam ParryKings College Hospital Foundation Trust, London, UK.
Kuhan PushparatnamExpert Through Experience, UK.
Natasha RatcliffeIndependent Advisor, Manchester, UK.
Dorothy SalathielExpert Through Experience, UK.
Paula ScurfieldExpert Through Experience, UK.
Carroll SiuExpert Through Experience, UK.
Sue WhippsExpert Through Experience, UK.
Sheila WonnacottExpert Through Experience, UK.
Thomas FoltynieUniversity College London, London, UK.
Camille B CarrollUniversity of Plymouth, Plymouth, UK.
Kevin McFarthingExpert Through Experience, UK.
EJS ACT-PD consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patient and public involvement and engagement (PPIE) in the design of trials is important, as participant experience critically impacts delivery. The Edmond J Safra Accelerating Clinical Trials in PD (EJS ACT-PD) initiative is a UK consortium designing a platform trial for disease modifying therapies in PD. Objective: The integration of PPIE in all aspects of trial design and its evaluation throughout the project. Methods: PwP and care partners were recruited to a PPIE working group (WG) via UK Parkinson's charities, investigator patient groups and participants of a Delphi study on trial design. They are supported by charity representatives, trial delivery experts, researchers and core project team members. PPIE is fully embedded within the consortium's five other WGs and steering group. The group's terms of reference, processes for effective working and PPIE evaluation were co-developed with PPIE contributors. Results: 11 PwP and 4 care partners have supported the PPIE WG and contributed to the development of processes for effective working. A mixed methods research-in-action study is ongoing to evaluate PPIE within the consortium. This includes the Patient Engagement in Research Scale -a quantitative PPIE quality measure; semi-structured interviews -identifying areas for improvement and overall impressions of involvement; process fidelity- recording adherence; project documentation review - identifying impact of PPIE on project outputs. Conclusions: We provide a practical example of PPIE in complex projects. Evaluating feasibility, experiences and impact of PPIE involvement in EJS ACT-PD will inform similar programs on effective strategies. This will help enable future patient-centered research.

Indexed as

Clinical Trials as TopicParkinson DiseasePatient ParticipationAdaptive Clinical Trials as TopicCommunity ParticipationDelphi TechniqueHumansResearch DesignUnited Kingdomclinical trial protocolEvaluation studyParkinson’s diseasepatient and public involvement

Identifiers

PMID38701161
PMCPMC11191543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.